Patient Selection Criteria: Identifying Appropriate Candidates for Tarlatamab
Panelists discuss how tarlatamab eligibility is determined based on clinical factors such as prior treatment history, organ function, and ECOG performance status, with particular attention to how previous therapies, such as chimeric antigen receptor T-cell therapy or chemotherapy, may affect eligibility and immune system response.
EP: 1.ES-SCLC vs LS-SCLC: Critical Differences in Disease Burden and Patient Prognosis
EP: 2.Current Treatment Paradigm: Evolution of First-Line Therapy for ES-SCLC
EP: 3.Addressing Critical Unmet Needs in ES-SCLC Patient Management
EP: 4.Emerging Clinical Trials: Novel Approaches in Second-Line ES-SCLC
EP: 5.Institutional Implementation: Setting Up Tarlatamab Administration
EP: 6.Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
EP: 7.Patient Selection Criteria: Identifying Appropriate Candidates for Tarlatamab
EP: 8.Tarlatamab Administration and Postinfusion Monitoring
Summary for Physicians:
Clinical Factors for Tarlatamab Eligibility:
- Good candidates:
- Relapsed/refractory small cell lung cancer after prior treatments
- Adequate organ function (eg, liver, kidney)
- ECOG performance status: Typically 0-1 (able to carry out normal activities or minimal assistance needed)
- Impact of treatment history:
- Chimeric antigen receptor T-cell therapy or bispecifics: May affect eligibility due to prior immune system manipulation; consider potential cross-reactivity or previous toxicities.
- Chemotherapy: Previous treatment may influence eligibility, especially if there are complications (eg, neuropathy or compromised organ function).
Prior therapies may also alter immune system response, impacting effectiveness.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
